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Background: The original EULAR recommendations for the management of fibromyalgia assessed 
evidence up to and including 2005. The paucity of information at that time meant that most 
recommendations were “expert opinion”. We now update the recommendations taking account of 
the many randomised controlled trials (RCT) conducted since that time.  
Methods: A multidisciplinary group from 12 European countries assessed the available evidence and 
the focus was on systematic reviews and meta-analyses concerned with the pharmacological, non-
pharmacological management or complementary and alternative medicine or therapies for 
fibromyalgia. A review using seven electronic databases was undertaken up to May 2015 and articles 
identified as eligible were assessed for quality. The key outcomes assessed were pain, fatigue, sleep 
and daily functioning. The Grading of Recommendations Assessment, Development and Evaluation 
(GRADE) system was used for making recommendations: strong for/weak for/ weak against/ strong 
against or allowing a recommendation “use only for research” 
Results: A total of 2979 titles were identified.  From these, 571 abstracts and then 275 full papers were 
selected for review, and 107 reviews (and/or meta-analyses) evaluated as eligible.  A graduated 
approach, following four main stages is suggested underpinned by shared decision-making with 
patients. Initial management should involve patient education and be focussed on non-
pharmacological therapies. The only “strong for” therapy-based recommendation in the guidelines 
was for exercise. In case of non-response, further therapy should be tailored to the specific needs of 
the individual and may involve psychological therapies (for mood disorders and unhelpful coping 
strategies), pharmacotherapy (for severe pain or sleep disturbance) and/or a multimodal 
rehabilitation programme (for severe dysfunction).  
Conclusion: This update allows EULAR to base recommendations for the management of fibromyalgia 
on scientific evidence from high-quality reviews and meta-analyses. However, the size of effect for 
many treatments is relatively modest. We propose research priorities clarifying who will derive benefit 
from specific interventions, their effect in combination, and the organisation of health care systems 
to optimise outcome. 
 
 Introduction 
Fibromyalgia is common with a prevalence of 2% in the general population (Queiroz, 2013; Wolfe et 
al, 1995). However, its diagnosis and management remain a challenge for patients and healthcare 
professionals. It often takes more than 2 years for a diagnosis to be made with an average of 3.7 
consultations with different physicians (Choy et al, 2010). Referral to specialists and investigations 
results in high healthcare utilisation, for up to 10 years prior to diagnosis, when compared with 
persons who do not have fibromyalgia (Boonen et al, 2005). Although pain is the dominant symptom 
in fibromyalgia, other symptoms such as fatigue, non-refreshed sleep, mood disturbance and cognitive 
impairment are common, but not universal, have an important influence on quality of life, and 
emphasize that it is a heterogeneous and complex condition (Hauser et al, 2008; Fietta et al, 2007). 
The original EULAR recommendations for the management of fibromyalgia assessed evidence up to 
and including 2005 (Carville et al, 2008) Given the paucity of information and poor quality of the 
studies available, it was recommended that the guidelines be revised after a period of 4 years. 
However no subsequent revision took place and thus a decade later we revisit the recommendations 
with the aim of making them more evidence-based. In the time since the original recommendations 
there have been a considerable number of individual trials examining pharmacological and non-
pharmacological interventions and, moreover, there have been systematic reviews conducted for 
nearly all of the commonly used management strategies. Our aim therefore was, using the systematic 
reviews conducted and taking into account their quality, to make evidence-based recommendations 
for the use of individual pharmacological and non-pharmacological approaches, and how these could 
be combined. Further we aimed to identify priority areas for future research. 
 
Methods 
Working group membership 
The working group included members from 12 European countries: clinicians (representing 
rheumatology, internal medicine, pain medicine and epidemiology), non-clinical scientists 
(occupational health, epidemiology), patient representatives, and the allied health professions 
(nursing). 
Eligibility, search strategy and quality assessment 
We focused on systematic reviews (with or without meta-analysis) concerned with the management 
of fibromyalgia. Details of eligibility, review and quality assessment is provided in supplementary text 
available on-line.  
Evaluating evidence 
We retained pain as one of the key outcomes of interest, from the original guidelines, but also included 
fatigue, sleep and daily functioning. The committee considered the following in making a 
recommendation: number of trials; number of patients; outcomes assessed; quality of reviews and 
the trials included within the reviews; effect size (and 95% CI); adverse events; cost. We used the 
Grading of Recommendations Assessment, Development and Evaluation (GRADE) system for making 
recommendations (Guyatt et al, 2011). This is a 4-point scale: strong for/weak for/ weak against/ 
strong against; or allowing a recommendation “use only for research”.  The strength of 
recommendation is based on the balance between desirable and undesirable effects (considering 
values and preferences), confidence in the magnitude of effects and resource use.  A strong 
recommendation implies that, if presented with the evidence, all or almost all informed persons would 
make the recommendation for or against the therapy, while a weak recommendation would imply 
that most people would, although a substantial minority would not (Andrews et al, 2013). 
Two sub-groups considered the evidence for pharmacological and non-pharmacological therapies and 
proposed a recommendation. At a face-to-face meeting, after presentation of the evidence and the 
preliminary recommendation, discussion resulted in a “final recommendation”. In addition to the 
evidence on efficacy/effectiveness, the committee also took into account availability, cost, sustained 
effects and safety. All participants then voted on their level of agreement with the recommendation 
on a scale from 0 “completely disagree” to 10 “completely agree”. The percentage of the committee 
scoring at least 7 was taken to indicate level of agreement. 
 
Results 
In total, 2979 titles were identified.  From these, 571 abstracts and then 275 full papers were selected 
for review, and 107 reviews evaluated as eligible for consideration in making recommendations for 
management (Figure 1). 
Evaluation of pharmacological medicines 
Information on the reviews informing these recommendations on pharmacological therapy is collated 
in Supplementary Table A and information from one review, for each medicine, selected based on 
recency and quality is provided in Table 1.  
Amitriptyline: Five reviews included up to 13 trials and a maximum of 919 subjects. Hauser et al (2011) 
reported that patients receiving amitriptyline were more likely to achieve 30% pain reduction (RR 1.60, 
95% CI (1.15,2.24)), equivalent to a “number needed to treat” (NNT) of 3.54 95% CI (2.74, 5.01). There 
was a moderate effect on sleep (SMD -0.56, 95% CI -0.78,-0.34)1 and small effect on fatigue (-0.44; -
0.71, -0.16). There was no difference in discontinuation rates compared to patients receiving placebo. 
Nishishinya et al (2008) in their high-quality review concluded that 25mg/day improved pain, sleep 
and fatigue at 6-8 weeks of treatment but not at 12 weeks while 50 mg/day did not demonstrate 
efficacy  Amitriptyline Evaluation: Weak for, at low dose (100% agreement) 
Anticonvulsants: Nine reviews of pregabalin included up to 7 studies and a maximum of 3344 patients. 
A recent Cochrane review (Üçeyler et al, 2013) reported patients receiving active treatment were 
more likely to have 30% pain reduction RR 1.37 95% CI (1.22, 1.53) with a “number needed to benefit” 
(NNTB) over placebo of 9 95% CI (7, 13). There was a very small effect on fatigue (-0.17; -0.25, -0.09) 
and small effect on sleep (-0.35; -0.43, -0.27) but no effect on disability (-0.01; -0.11, 0.09).  A single, 
moderate quality, study of gabapentin in 150 subjects (e.g. in Moore, et al, 2014) showed a significant 
                                                          
1 All effect sizes are expressed as SMD with 95% CI unless otherwise stated.  
effect on 30% pain reduction (RR 1.65 95% CI 1.10, 2.48), a small effect on sleep (-0.71; -1.08, -0.24) 
and a large effect on disability (-0.94; -1.32, -0.56). Anticonvulsant Evaluation: Pregabalin - Weak for 
(94% agreement); Gabapentin – Research only (100% agreement) 
Cyclobenzaprine: A single systematic review of 5 studies involving 312 patients reported that of those 
taking cyclobenzaprine 85% experienced side effects and only 71% completed the studies. They were 
more likely to report themselves as “improved” (NNT 4.8 95% CI (3.0, 11.0)). Only two studies reported 
an “intention-to-treat” (ITT) analysis. Sleep, but not pain,  showed a significant, very small, 
improvement relative to baseline at the longest outcome considered (12 weeks: SMD 0.34) and 
patients on placebo showed  similar improvement (SMD 0.52) (Tofferi et al, 2004). Cyclobenzaprine 
Evaluation: Weak for (75% agreement) 
Growth hormone: A single systematic review of 2 studies involving 74 patients reported an effect size 
on pain of 1.36 (0.01, 1.34)(Perrot and Russell, 2014). The improvement in functional deficit was not 
statistically significant (1.24; −0.36, 2.84).  There are concerns on safety (sleep apnoea, carpal tunnel 
syndrome).  The drug is not approved for FM or related disorders in Europe. Growth hormone 
Evaluation: Strong against (94% agreement) 
Monoamine Oxidase Inhibitors (MAOIs): Four reviews identified up to 3 studies and 241 patients. 
Hauser et al (2009b) reported a moderate effect on pain across the studies (-0.54; -1.02, - 0.07), but 
the single studies which evaluated fatigue and sleep showed no effect. There were no differences in 
dropouts or adverse events compared with placebo. There was no comparison between compounds. 
Life-threatening interactions have been documented. MAOIs Evaluation: Weak against (81% 
agreement) 
NSAIDs: A single review (Choy et al, 2011) identified two small trials with no evidence of improved 
outcome compared to placebo (Choy et al, 2011). One low quality review was not considered NSAIDs 
Evaluation: Weak against (100% agreement) 
Serotonin-Noradrenalin re-uptake inhibitors (SNRIs): Eight systematic reviews were identified which 
presented data separately for duloxetine.  The largest review of 2249 subjects (Lunn et al, 2014) 
reported duloxetine, short term (up to 12 wks)and long-term (up to 28 wks), was more effective than 
placebo at reducing pain (RR > 30% pain RR 1.38, 95% CI 1.22, 1.56) although there was no significant 
effect at 20-30 mg/day and no difference between doses of 60 and 120 mg/day. NNTB, based on 
60mg/day up to 12 weeks, was 6 95% CI (3, 12). A previous review reported small effects on sleep ( -
0.24; -0.37,-0.12) and disability (-0.33; -0.43,-0.24) but no effect on fatigue (Hauser et al, 2013). Seven 
systematic reviews were identified of milnacipran, a recent one of which evaluated 5 trials (Hauser et 
al, 2013). Patients taking milnacipran were more likely, at the end of treatment, to have  30% pain 
reduction (RR 1.38, 95% CI 1.25, 1.51) but there was only a small benefit on fatigue (-0.14; -0.19, -
0.08), disability (-0.16; -0.23,-0.10) and no effect on sleep. Duloxetine and Milnacipran Evaluation: 
Weak for (100% agreement) 
Selective Serotonin Reuptake Inhibitors (SSRIs): Seven systematic reviews included up to 11 trials and 
a maximum of 521 subjects. Given that reviews have not focussed on specific drugs or comparisons, 
drugs within this class were considered together. The most recent review, of medium quality included 
7 trials and reported that patients receiving SSRIs were more likely to achieve 30% pain reduction (RR 
1.59, 95% CI (1.01,2.52)), equivalent to a NNTB of 6.3 95% CI (4.1, 13.1). There was a moderate effect 
on sleep (-0.56; -0.78,-0.34) and no effect on fatigue (-0.17; -0.46, 0.11)(Perrot and Russell, 2014). SSRI 
Evaluation: Weak against (94% agreement) 
Sodium Oxybate: A single systematic review of 5 studies including 1535 patients reported small effects 
sizes on pain (0.44; 0.31, 0.58], sleep problems  (0.47; 0.28, 0.66)  and fatigue [0.48; 0.35, 0.60). EMA 
and FDA refused the approval for FM because of safety concerns (Perrot and Russell, 2014). The drug 
is only approved for narcolepsy. Sodium Oxybate evaluation: Strong against (94% agreement) 
Tramadol, a weak opioid with mild SNRI activity, was considered by two reviews. Roskell et al (2011) 
identified a single study of tramadol with paracetamol. Those in the active arm were more likely to 
have 30% improvement in pain (RR 1.77 95% CI 1.26, 2.48).  Tramadol Evaluation: Weak for (100% 
agreement) 
The literature search did not identify any reviews on corticosteroids, strong opioids, cannabinoids, and 
anti-psychotics. The committee made a “Strong against” evaluation (100% agreement) regarding the 
use of strong opioids and corticosteroids in patients with fibromyalgia, on the basis of lack of evidence 
of efficacy and high risk of side effects/addiction reported in individual trials.  
Evaluation of non-pharmacological therapies; complementary and alternative medicines and 
therapies 
Information on the reviews informing these recommendations on non-pharmacological, 
complementary and alternative medicines and therapies is collated in Supplementary Table B and 
information from one review, for each individual therapy, selected based on recency and quality is 
provided in Table 2. 
Acupuncture: Eight reviews included up to 16 trials and 1081 participants.  One high quality review 
included nine trials, with 395 patients and demonstrated that acupuncture, added to standard therapy 
resulted in a 30% (21%, 39%) improvement in pain (Deare et al 2013).  Electric acupuncture was also 
associated with improvements in pain (22%; 4%, 41%), stiffness (9%; 4%, 16%) and fatigue (11%; 2%, 
20%).  Some adverse events were reported, but these were commonly mild and transient.  There is 
little understanding of the active component of acupuncture, and the evidence supporting the use of 
real versus sham acupuncture was less consistent.  Acupuncture evaluation: Weak for (93% 
agreement). 
Biofeedback: Two reviews included up to seven trials and 307 participants.  Glombiewski et al (2013) 
reviewed seven studies, comprising 321 participants.  Treatment sessions varied from 6-22; with 
control therapy comprising sham biofeedback, attention control, medication, and treatment as usual.  
Biofeedback was effective in reducing pain intensity (Hedges’ g = 0.79; 0.22, 1.36) although all trials 
were poor quality.  There was no evidence of effectiveness in terms of fatigue, sleep, depression, or 
quality of life, and sub-group analysis suggested that any effect was limited to electromyographic 
(0.86; 0.11, 1.62) rather than electroencephalographic biofeedback (0.71; -0.37, 1.8).  Biofeedback 
evaluation: weak against (100% agreement). 
Capsaicin: Two reviews included two trials and 153 participants.  The most recent review, a narrative 
review of two trials, considered data on 153 patients (De Souza Nascimento et al 2013).  Both showed 
some evidence of positive effect in terms of pain relief, although results were not consistent for other 
outcomes.  Capsaicin gel is generally considered safe, although many users report a mild burning 
sensation when applied to the skin. However, the number of patients and trials was small and were 
therefore limited in the extent to which they can provide evidence for toxicity.  Capsaicin evaluation: 
Weak against (86% agreement). 
Chiropractic: Three reviews included up to 13 trials and 102 participants.  The most recent review 
summarised three studies (Ernst et al 2009).  One study was an open pilot study, one quasi-
randomised, and in the third no between-group differences were observed in terms of pain, 
tenderness and Fibromyalgia Impact Questionnaire.  The studies were poor quality and lacked robust 
interpretable data.  Chiropractic evaluation: Strong against (93% agreement). 
Cognitive behavioural therapies (CBTs): Five reviews included up to 30 trials and at least 2031 
participants.  One high quality review included 23 trials, comprising >2000 patients, although the 
quality of individual trials was reported as generally poor (Bernardy et al 2013).  CBTs were effective 
in reducing pain (-0.29; -0.49, -0.17), disability (-0.30; -0.51, -0.08) and negative mood (-0.33; -0.49, -
0.17) at the end of treatment, compared to a variety of controls groups, and results were sustained 
long term.  Behavioural therapy evaluation: Weak for (100% agreement). 
Exercise: 20 reviews included up to 34 trials and at least 2494 participants2.  The largest, a Cochrane 
review, considered 47 different exercise interventions (Busch et al 2008).  Aerobic exercise was 
associated with improvements in pain (0.65; -0.09, 1.39), physical function (0.66; 0.41, 0.92), well-
being (0.49; 0.23, 0.75) and tender-points (0.23; -0.18, 0.65).  Busch et al (2013) reviewed five trials 
with 219 participants and concluded that resistance training resulted in a significant improvement in 
pain, compared to control (-3.3cm on a 10cm scale; -6.35, -0.26) as well as function, tenderness and 
strength.  There is some consistency with regards to aerobic and strengthening exercises, although 
insufficient evidence to suggest superiority of one over the other; land and aquatic exercise appear 
equally effective. (Bidonde et al 2014).  Exercise therapy evaluation: Strong for (100% agreement). 
Hydrotherapy / spa therapy: Four reviews included up to 21 trials and 1306 participants.  One high 
quality review included ten trials, 446 participants, and compared a median of 4hrs hydrotherapy 
(range 200-300mins) against various comparators (Langhorst et al 2009).  There was a significant 
improvement in pain (-0.78; -1.42, -0.13) and health-related quality of life (-1.67; -2.91, -0.43) at the 
end of therapy, maintained in the longer term (median 14 weeks), although the review authors noted 
that no trials conducted an ITT analysis..  There was consistency with regards to the evidence for 
hydrotherapy and balneotherapy, although little evidence to suggest superiority of one over the other 
(Naumann and Sadaghiani 2014).  Hydrotherapy evaluation: Weak for (93% agreement). 
Hypnotherapy: One review included four trials, although the number of participants is unclear 
(Bernardy et al 2011).  Although six trials of hypnotherapy and/or guided imagery were reviewed, only 
four examined hypnotherapy in isolation.  Median treatment duration (where reported) was 360 
minutes and hypnotherapy was compared with a variety of control therapies: cognitive intervention, 
active control (physical therapy / massage / relaxation / autogenic training), and treatment as usual.  A 
meta-analysis is presented on all six trials, and isolated data for hypnotherapy is not presented.  Two 
of the four hypnotherapy trials report some significant benefit in terms of pain, the other two 
demonstrate null, non-significant results.  Hypnotherapy evaluation: Weak against (86% agreement). 
                                                          
2 It is unclear from some of the reviews how many participants were included.  The number of participants 
represents the minimum about which we can be confident. 
 Massage: Six reviews have been reported and  one meta-analysis with nine trials and 404 patients (Li 
et al 2014) with sessions lasting 25-90 mins, and treatment duration ranging from 1-24 weeks (median 
five weeks).  Comparator treatments, included TENS, standard care, guided relaxation and 
acupuncture.  Methodological problems were noted with all of the studies, only four were at low risk 
of bias in terms of random allocation, and only two were analysed as ITT.  Overall, massage was not 
associated with a significant improvement in pain (0.37; -0.19, 0.93) and of the two ITT analyses, one 
favoured massage and one favoured control (both significant).  A sub-group analysis revealed some 
evidence of a positive effect with massage of ≥5 weeks duration, although this was based solely on 
lower quality trials.  Massage evaluation: Weak against (86% agreement). 
Meditative movement: Six reviews, including up to eight trials and 559 participants focused on qigong, 
yoga, tai chi, or a combination of these therapies.  However, there was insufficient evidence to make 
individual recommendations.  One review included 7 trials, with 362 participants randomised to tai 
chi, yoga, qigong, or body awareness therapy (Langhorst et al 2013). Total treatment time ranged from 
12-24hrs and was compared to a variety of controls, including treatment as usual and active control 
groups (aerobics, wellness education and stretching).  At the end of therapy, improvements were seen 
in sleep (-0.61; -0.95, -0.27), fatigue (-0.66; -0.99, -0.34), and quality of life (-0.59; -0.93, -0.24) some 
of which were maintained in the longer term.  Meditative movement evaluation: Weak for (71% 
agreement). 
Mindfulness / mind-body therapy: Six reviews included up to 13 trials and 1209 participants.  One 
recent review, a meta-analysis of 6 trials, with 674 patients (Lauche et al 2013b) provided evidence 
that mindfulness-based stress reduction resulted in improvements in pain ( -0.23; -0.46, -0.01) and 
quality of life (-0.35; -0.57, -0.12) immediately post-treatment, when compared to usual care, and 
when compared to active control interventions (-0.44; -0.73, -0.16, and -0.32; -0.59, -0.04, 
respectively).  However, these effects were not robust against bias.  Mindfulness / mind-body therapy 
evaluation: Weak for (73% agreement). 
Multi-component therapy: Two reviews including up to 27 trials and 2407 participants examined the 
additional benefit of combining therapies, compared to individual therapy.  Häuser et al (2009a) 
conducted a review of management involving both educational or psychological therapies and 
exercise.  In a meta-analysis of nine trials and 1119 patients, multi-component therapy was effective 
in reducing pain (-0.37; -0.62, -0.13), and fatigue and depression, immediately post-treatment, 
compared to waiting-list, relaxation, treatment as usual, and education.  It also was associated with 
improvements in quality of life, self-efficacy and fitness.  However, for most outcomes, effects were 
short-lived.  Multi-component therapy evaluation: Weak for (93% agreement). 
S-Adenosyl methionine (SAMe): Two reviews each included one trial with, in combination, 74 
participants.  De Silva et al (2010) reported that, after the end of treatment, significant improvements 
were observed in pain, fatigue, disease activity, stiffness and mood compared to placebo.  Sim and 
Adams (2002) reviewed a trial comparing SAMe with transcutaneous electrical nerve stimulation 
(TENS) but data on the main trial comparison is omitted.  Side-effects are usually mild and infrequent.  
However, the number of patients and trials were small and therefore cannot provide a robust 
assessment of toxicity and safety.  SAMe evaluation: Weak against (93% agreement). 
Other complementary and alternative therapies: Three reviews of guided imagery included up to six 
trials and 357 participants.  The highest quality, including only one trial, provided some evidence that 
guided imagery may be effective in reducing pain ( -1.52; -2.17, -0.87) and quality of life (-2.51; -3.28, 
-1.74) (Bernardy et al 2011). Two reviews of homeopathy, including four trials and 163 participants 
(Perry et al 2010; Boehm et al 2014).  Both contained a review including only four randomised trials, 
each of which showed some benefit of homeopathy, on some outcomes.  However, none of the 
individual trials were without serious flaws.  Other complementary and alternative therapies (guided 
imagery, homeopathy): strong against (93% agreement). 
Reviews were identified that examined electrothermal and phototherapeutic therapy (Ricci et al 
2010); phytothermotherapy (Tenti et al 2013); music therapy, journaling/story-telling (Crawford et al 
2014), and static magnet therapy (Eccles et al 2005), although each was insufficient to allow a 
recommendation. Marlow et al (2013) examined the effectiveness of transcranial magnetic and/or 
direct current stimulation.  Eight trials included 244 participants, although not all were analysed by 
ITT, and appropriate group comparisons were not presented for all studies.  Overall, there was little 
evidence to support either therapy, and several studies reported an unacceptably high rate of adverse 
events and/or discontinuation due to headache. 
EULAR Revised Recommendations: 
In terms of overall principles we recommend, based on unanimous expert opinion, that optimal 
management requires prompt diagnosis, and providing the patient with information (including written 
material) about the condition. There should be a comprehensive assessment of pain, function, and 
the psychosocial context.  Management should take the form of a graduated approach with the aim 
of improving health-related quality of life. It should focus firstly on non-pharmacological modalities. 
This is based on availability, cost, safety issues and patient preference. We have used the evaluation 
of individual therapies (above) to make ten specific recommendations, all based on evidence from 
systematic reviews and all but one from meta-analysis. The recommendations are given in Table 3 and 
a flow chart of how these therapies may be used in management is shown in Figure 2.  
We were unanimous in providing a “strong for” recommendation for the use of exercise, particularly 
given its effect on pain, physical function and well-being, availability, relatively low cost and lack of 
safety concerns. The available evidence did not allow us to distinguish between the benefits of aerobic 
or strengthening. We gave “weak for” recommendations in relation to meditative movement 
therapies (which improved sleep, fatigue and quality of life) or mindfulness-based stress reduction 
(which improved pain and quality of life); the physical therapies acupuncture or hydrotherapy for 
which there was evidence that they improved pain/fatigue and pain/quality of life respectively. We 
also gave a “weak for” recommendation to multi-component therapies which, in comparison, to 
individual therapies improved a range of short-term outcomes. The effects seen in pragmatic trials of 
such therapies, will include specific and non-specific effects and it is not possible to disentangle these. 
There were some non-pharmacological therapies we did not recommend because of lack of 
effectiveness: biofeedback, capsaicin, hypnotherapy, massage, SAMe and other complementary and 
alternative therapies. We provided a “strong against” evaluation for chiropractic based on safety 
concerns.  
In case of lack of effect of non-pharmacological therapy, we recommend individualized treatment 
according to patient need. Psychological therapies (“weak for”) should be considered for those with 
mood disorder or unhelpful coping strategies: CBT was effective at producing modest, long-term 
reductions in pain, disability and improving mood. Pharmacological therapies (all “weak for”) should 
be considered for those with severe pain (duloxetine, pregabalin, tramadol) or sleep disturbance 
(amitriptyline, cyclobenzaprine, pregabalin) , while  multimodal rehabilitation (“weak for”) programs 
should be considered for those with severe dysfunction. We did not recommend several 
pharmacological therapies including NSAIDs, MAOIs, SSRIs, because of lack of efficacy and specifically 
gave a “strong against” evaluation to growth hormone, sodium oxybate, strong opioids and 
corticosteroids based on lack of efficacy and high risk of side effects.   
Discussion 
The previous EULAR recommendations provided an important milestone in the management of 
fibromyalgia. There were nine recommendations, but only three were supported by strong evidence 
from the scientific literature; most were based on expert opinion. Since that time there have been a 
considerable number of trials published addressing issues in the management of fibromyalgia. The 
availability of systematic reviews and meta-analysis of RCTs for all the most common approaches to 
management allowed us to concentrate on these.  
Comparison with 2007 EULAR Recommendations 
Despite the very large increase in the amount of trial data and summarised in meta-analyses, there 
are no major changes to the approach of managing patients with fibromyalgia. However all the 
recommendations are now firmly evidence-based. This evidence provides support for some additional 
non-pharmacological therapies. We now recommend that non-pharmacological therapy should be 
first-line therapy and then if there is a lack of effect that there should be individualised therapy 
according to patient need, which may include pharmacological therapy. 
Comparison with other recommendation 
There are three recent guidelines on the management of FM from Canada, Israel and Germany which 
have been compared with respect to their recommendations (Ablin et al, 2013). These guidelines and 
our EULAR recommendations are in agreement on the principles of approach to management, the 
need for tailored therapy to the individual and the first-line role of non-pharmacological therapies. 
There are differences between our guidelines and previous, which can partly be explained by us using 
more recently available evidence. There are differences in the strength of recommendations relating 
to pharmacological therapies: anticonvulsants and SNRIs were strongly recommended by the 
Canadian and Israeli guidelines while the German and these EULAR guidelines provide a weak 
recommendation.  There are also differences in relation to individual non-pharmacological therapies 
across guidelines in terms of whether they were assessed. For example meditative movement is 
strongly recommended by the German guidelines, but recommended only for a minority of patients 
in Israel, while these EULAR guidelines provide a “weak for” recommendation. 
The committee recommend that an update is conducted after 5 years in order to determine whether 
for those therapies with relatively little current evidence, further trials have been conducted and 
secondly whether any new therapies have emerged for the management of fibromyalgia 
Research priorities 
In the course of discussion we identified important questions in terms of guiding management where 
there was either insufficient (or often no) evidence base to guide decisions i.e. “research gaps”. We 
discussed their relatively priority taking into account their potential to guide management, the 
likelihood that such studies could be conducted and were likely to be funded. We identified five such 
priority questions: 
• Which type of exercise is most effective: strength and/or aerobic training? 
• Is combined pharmacological and non-pharmacological approaches to management more 
effective than single modality management? 
• Are there characteristics of patients with fibromyalgia which predict response to specific 
therapies? 
• How should fibromyalgia be managed when it occurs as a co-morbidity to inflammatory 
arthritis? 
• What aspects of a healthcare system optimise outcome for patients (who is best for the 
management of FM patients?) 
Some of these questions are best answered by randomised controlled trials. Given, however the 
expense of such studies and that they can take almost 10 years from identifying the questions to be 
answered to results being obtained, alternatives including registers and observational studies should 
be considered. These can be complemented by qualitative studies to determine the needs of patients.  
Dissemination 
These recommendations will be disseminated, by the international working group, through national 
rheumatology societies. This will include scientific meetings, newsletters, continuing education 
programmes. We will produce a summary of the recommendations suitable for dissemination through 
EULAR-affiliated patient groups and through national patient societies. We will investigate assessing 
agreement with the recommendations in the target population.  
Summary 
In summary, these revised EULAR recommendations newly incorporate a decade of evidence in 
relation to the pharmacological and non-pharmacological management of fibromyalgia. They allow 
EULAR to move from recommendations which are predominantly based on expert opinion to ones 
which are firmly based on scientific evidence from high-quality reviews and meta-analyses. Despite 
this evidence, however, the size of effect for many treatments is relatively modest .We propose 
focussing on the research priorities we outline to address issues clarifying to whom certain 
interventions may best be delivered, their effect in combination, matching patients to therapies and 
the organisation of health care systems to optimise outcome. 
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